Light Mode
$0.0021 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0021, and at the day’s high of $0.0025
-0.01 (-70.42%) / 6M
Momentum, market sentiment, and recent alerts
PTPI reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -89.6%.
No alerts for PTPI in the last day.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharma co-vigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
